Study of the Impact of Indacaterol (Onbrez®) on the Individual Lives and Health Status of Patients With COPD
Last updated on April 2022Recruitment
- Recruitment Status
- Completed
Inclusion Criteria
- Patients with active diagnosis of COPD, confirmed by spirometry documented in medical notes
- Patients with active diagnosis of COPD, confirmed by spirometry documented in medical notes
Exclusion Criteria
- Patients previously prescribed Indacaterol.
- Patients who are currently receiving other maintenance therapy (except LAMA) for COPD.
- Patients previously prescribed Indacaterol.
- Patients who are currently receiving other maintenance therapy (except LAMA) for COPD.
Summary
- Conditions
- Chronic Obstructive Pulmonary Disease
- Type
- Observational
- Design
- Observational Model: Cohort
- Time Perspective: Prospective
Participation Requirements
- Age
- Younger than 125 years
- Gender
- Both males and females
Inclusion Criteria
- Patients with active diagnosis of COPD, confirmed by spirometry documented in medical notes
- Patients with active diagnosis of COPD, confirmed by spirometry documented in medical notes
Exclusion Criteria
- Patients previously prescribed Indacaterol.
- Patients who are currently receiving other maintenance therapy (except LAMA) for COPD.
- Patients previously prescribed Indacaterol.
- Patients who are currently receiving other maintenance therapy (except LAMA) for COPD.
Tracking Information
- NCT #
- NCT02123199
- Collaborators
- Not Provided
- Investigators
- Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals